Skip to main content

Table 2 Base case cost-effectiveness results

From: Cost-effectiveness and value of information analysis of NephroCheck and NGAL tests compared to standard care for the diagnosis of acute kidney injury

  Cost Incremental Cost QALY Incremental QALY ICER (incremental) ICER vs. standard care p (C/E) @ 20 k p (C/E) @ 20 k vs. standard care
Base case: Full associative effect of AKI mitigation on a) the risk of CKD within the first year, b) half the associative effect on the need for ICU, c) half the associative effect on hospital/ICU LOS, and d) no associative effect on 90-day mortality.
Standard care (Scr) £22,978 6.07277 64.5%
Test 1 (NephroCheck) £23,016 £38 6.07313 0.00036 £105,965 £105,965 29.7% 32.0%
Test 3 (NGAL urine - BioPorto) £23,049 Dominated 6.07290 Dominated Dominated £539,041 5.3% 11.0%
Test 2 (NGAL plasma - BioPorto) £23,064 Dominated 6.07290 Dominated Dominated £633,846 0.3% 7.3%
Test 4 (NGAL urine - ARCHITECT) £23,065 Dominated 6.07289 Dominated Dominated £725,061 0.0% 6.3%
  1. Dominated: more costly and less effective; P(C/E): probability that a test is cost-effective at a threshold value of willingness to pay for a QALY of £20,000